Phase III gene therapy trials enroll far fewer patients than other cardiovascular trials

Average patients enrolled versus planned for Phase III trials initiated 2013–2022

Phase III gene therapy cardiovascular trials

Average 139 subjects enrolled

Average 254 subjects planned

All Phase III cardiovascular trials

Average 732 subjects enrolled

Average 822 subjects planned

GlobalData